Management of isolated nonresectable liver metastases in colorectal cancer patients: A case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1662-1667

  van Iersel, L B J ^a   Koopman, M ^b   van de Velde, C J H ^a   Mol, L ^c   van Persijn van Meerten, E L ^a   Hartgrink, H H ^a   Kuppen, P J K ^a   Vahrmeijer, A L ^a   Nortier, J W R ^a   Tollenaar, R A E M ^a   Punt, C ^b   Gelderblom, H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Integraal Kankercentrum Oost   (Netherlands)

Author keywords

Chemotherapy; Colorectal cancer; Isolated hepatic perfusion; Liver metastases

Indexed keywords

CAPECITABINE; IRINOTECAN; MELPHALAN; OXALIPLATIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CASE CONTROL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; ISOLATED HEPATIC PERFUSION; LIVER DISEASE; LIVER METASTASIS; LIVER PERFUSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; CASE-CONTROL STUDIES; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MELPHALAN; MIDDLE AGED;

EID: 77955239765     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp589     Document Type: Article

References (27)

1. Punt CJ. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004; 15: 1453-1459.
2. Weiss L, Grundmann E, Torhorst J et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986; 150: 195-203.
3. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979; 189: 496-502.
4. Scheele J, Stang R, Altendorf-Hofmann A et al. Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71.
5. Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77: 1254-1262.
6. Yamamoto J, Shimada K, Kosuge T et al. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 1999; 86: 332-337.
7. Rothbarth J, Pijl ME, Vahrmeijer AL et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg 2003; 90: 1391-1397.
8. Alexander HR Jr., Bartlett DL, Libutti SK et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16: 1479-1489.
9. Alexander HR Jr., Libutti SK, Pingpank JF et al. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 2005; 12: 138-144.
10. Bartlett DL, Libutti SK, Figg WD et al. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001; 129: 176-187.
11. Vahrmeijer AL, van Dierendonck JH, Keizer HJ et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 2000; 82: 1539-1546.
12. Verhoef C, de Wilt JH, Brunstein F et al. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion. Ann Surg Oncol 2008; 15: 1367-1374.
13. Zeh HJ III, Brown CK, Holtzman MP et al. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol 2009; 16: 385-394.
14. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
15. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-142.
16. van Iersel LB, Verlaan MR, Vahrmeijer AL et al. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. Eur J Surg Oncol 2007; 33: 874-881.
17. van Iersel LB, Gelderblom H, Vahrmeijer AL et al. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol 2008; 19(6): 1127-1134.
18. Marinelli A, de Brauw LM, Beerman H et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 1996; 26: 341-350.
19. Runia RD, de Brauw LM, Kothuis BJ et al. Continuous measurement of leakage during isolated liver perfusion with a radiotracer. Int J Rad Appl Instrum B 1987; 14: 113-118.
20. Curley SA, Byrd DR, Newman RA et al. Reduction of systemic drug exposure after hepatic arterial infusion of doxorubicin with complete hepatic venous isolation and extracorporeal chemofiltration. Surgery 1993; 114: 579-585.
21. Ravikumar TS, Pizzorno G, Bodden W et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 1994; 12: 2723-2736.
22. Ku Y, Iwasaki T, Fukumoto T et al. Percutaneous isolated liver chemoperfusion for treatment of unresectable malignant liver tumors: technique, pharmacokinetics, clinical results. Recent Results Cancer Res 1998; 147: 67-82.
23. Pingpank JF, Libutti SK, Chang R et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005; 23: 3465-3474.
24. Savier E, Azoulay D, Huguet E et al. Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study. Arch Surg 2003; 138: 325-332.
25. van Etten B, Brunstein F, van IJken MG et al. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. Ann Surg Oncol 2004; 11: 598-605.
26. Rothbarth J, Pijl ME, Tollenaar RA et al. An experimental minimally invasive perfusion technique for the treatment of liver metastases. Eur J Surg Oncol 2003; 29: 757-763.
27. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. Journal of Clinical Oncology 2003; 21: 2059-2069.